Approach to Managing T Wave and QT Interval Abnormalities

QT Interval Assessment

The American College of Cardiology recommends using the Fridericia formula (QT divided by the cubic root of the RR interval) for heart rate correction, with normal QTc being <430 ms in males and <450 ms in females 1
QTc prolongation is graded as: grade 1 (450-480 ms), grade 2 (481-500 ms), and grade 3 (>501 ms), with QTc >500 ms or >60 ms increase from baseline associated with increased risk for torsades de pointes (TdP) 1
The FDA recommends using the Fridericia formula for heart rate correction 1

High-risk factors for TdP include QTc >500 ms or increase of >60 ms from baseline, electrolyte abnormalities (hypokalemia, hypomagnesemia, hypocalcemia), bradycardia or heart block, heart disease (especially LV hypertrophy, ischemia, low ejection fraction), female sex, older age, concomitant use of multiple QT-prolonging medications, and genetic predisposition (family history of long QT syndrome, syncope, or sudden death) 1, 4
The American College of Cardiology and the European Heart Journal recommend considering these high-risk factors when assessing patients for QT prolongation 1, 4, 5

The American College of Cardiology recommends obtaining baseline ECG and documenting QTc in medical record before starting potentially QT-prolonging therapies, correcting electrolyte abnormalities, and maintaining serum potassium between 4.5-5 mEq/L to shorten QT and reduce risk of TdP 1, 8
The European Heart Journal recommends discontinuing QT-prolonging medications when possible, and avoiding QT-prolonging medications in patients with congenital or acquired long QT syndrome 2, 5
The American College of Cardiology recommends monitoring ECG at 7 days after initiation of QT-prolonging therapy, and stopping treatment if QTc >500 ms on monitoring 1

For drug-induced QT prolongation, the Annals of Oncology recommend discontinuing the offending drug if QTc ≥500 ms or increases ≥60 ms from baseline, and avoiding QT-prolonging medications in patients with congenital or acquired long QT syndrome 3, 5
For congenital long QT syndrome, the European Heart Journal recommends prescribing beta-blockers as first-line therapy, considering left cardiac sympathetic denervation for patients with recurrent symptoms despite beta-blocker therapy, and considering ICD implantation for high-risk patients (QTc >500 ms, prior cardiac arrest, recurrent syncope) 5

The Annals of Oncology and the Journal of the American College of Cardiology recommend performing baseline ECG and repeat ECG at steady-state drug levels for patients on QT-prolonging medications, and monitoring ECG when initiating, adjusting doses, or adding new medications that may prolong QT 1, 3
The Journal of the American College of Cardiology recommends performing baseline ECG and periodic monitoring of QTc interval in cancer patients receiving QT-prolonging agents 1, 3

The American College of Cardiology and the European Heart Journal recommend performing individualized risk assessment before prescribing QT-prolonging drugs, using the lowest effective dose for the shortest possible time, avoiding potential drug interactions that may increase QT interval, and maintaining vigilance for QT prolongation in patients with risk factors 1, 4, 7